A case of primary neuroendocrine breast carcinoma that responded to neo-adjuvant chemotherapy

doi:10.1007/s11684-014-0345-z

Frontiers of Medicine

2015, Vol. 9

Issue (1): 112-116 https://doi.org/10.1007/s11684-014-0345-z

本期目录

A case of primary neuroendocrine breast carcinoma that responded to neo-adjuvant chemotherapy

Xiaolong Wei¹,Chunfa Chen^2,³,Didi Xi^2,³,Jinwen Bai^2,³,Wenhe Huang³,Luoxiang Rong^2,³,Mingyao Wu⁴,Guojun Zhang^2,^3,^*(

)

1. Department of Pathology, Cancer Hospital of Shantou University Medical College, Shantou 515031, China
2. Cancer Research Center, Shantou University Medical College, Shantou 515031, China
3. The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515031, China
4. Department of Pathology, Shantou University Medical College, Shantou 515031, China

全文: PDF(795 KB) HTML

Abstract：

Primary neuroendocrine breast carcinoma (NEBC) is a very rare type of breast cancer. Two characteristic biomarkers, namely, CgA and Syn, should be immunohistochemically detected to diagnose NEBC. In this study, a 43-year-old woman with a large mass of 8.3 cm × 2.9 cm in her right breast was reported. The patient was pathologically diagnosed with NEBC after specific markers, including CgA and Syn, as well as few differential markers, such as CK7, ER, PR, C-erbB-2, NSE, and E-cadherin, were immunohistochemically detected. The patient showed a remarkable response to four cycles of neo-adjuvant chemotherapy (partial response based on RECIST criteria) and sequentially underwent modified radical mastectomy. Moreover, the diagnosis and treatment of NEBC based on this case and available related literature were discussed.

Key words： neuroendocrine carcinoma neo-adjuvant therapy breast

收稿日期: 2014-04-04 出版日期: 2015-03-02

Corresponding Author(s): Guojun Zhang

引用本文:

. [J]. Frontiers of Medicine, 2015, 9(1): 112-116.
Xiaolong Wei,Chunfa Chen,Didi Xi,Jinwen Bai,Wenhe Huang,Luoxiang Rong,Mingyao Wu,Guojun Zhang. A case of primary neuroendocrine breast carcinoma that responded to neo-adjuvant chemotherapy. Front. Med., 2015, 9(1): 112-116.

链接本文:

https://academic.hep.com.cn/fmd/CN/10.1007/s11684-014-0345-z
https://academic.hep.com.cn/fmd/CN/Y2015/V9/I1/112

Fig.1

Fig.2

Fig.3

1	Feyrter <?Pub Caret1?> F, Hartmann G. On the carcinoid growth form of the carcinoma mammae, especially the carcinoma solidum (gelatinosum) mammae. Frankf Z Pathol 1963; 73: 24–39(in German) pmid: 14097474
2	Fisher ER, Palekar AS. Solid and mucinous varieties of so-called mammary carcinoid tumors. Am J Clin Pathol 1979; 72(6): 909–916 pmid: 229725
3	Azzopardi JG, Muretto P, Goddeeris P, Eusebi V, Lauweryns JM. ‘Carcinoid’ tumours of the breast: the morphological spectrum of argyrophil carcinomas. Histopathology 1982; 6(5): 549–569 https://doi.org/10.1111/j.1365-2559.1982.tb02750.x pmid: 6183185
4	Papotti M, Macrì L, Finzi G, Capella C, Eusebi V, Bussolati G. Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. Semin Diagn Pathol 1989; 6(2): 174–188 pmid: 2503862
5	Zadro Z, Fuduri? J, Frketi? I, Stifter S, Bujas T, Zadro AS, Veir Z, Doko I. Neuroendocrine small cell carcinoma of the breast—a case report. Coll Antropol 2012; 36(3): 1053–1055 pmid: 23213972
6	B?cker W. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol 2002; 86: 116–119 (in German) pmid: 12647359
7	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228–247 https://doi.org/10.1016/j.ejca.2008.10.026 pmid: 19097774
8	Fujimoto Y, Yagyu R, Murase K, Kawajiri H, Ohtani H, Arimoto Y, Yamamura T, Inoue T, Moritani S. A case of solid neuroendocrine carcinoma of the breast in a 40-year-old woman. Breast Cancer 2007; 14(2): 250–253 https://doi.org/10.2325/jbcs.889 pmid: 17485914
9	Adams RF, Parulekar V, Hughes C, Kadour MJ, Talbot D. Radiologic characteristics and management of screen-detected metastatic carcinoid tumor of the breast: a case report. Clin Breast Cancer 2009; 9(3): 189–192 https://doi.org/10.3816/CBC.2009.n.032 pmid: 19661045
10	Sapino A, Righi L, Cassoni P, Papotti M, Pietribiasi F, Bussolati G. Expression of the neuroendocrine phenotype in carcinomas of the breast. Semin Diagn Pathol 2000; 17(2): 127–137 pmid: 10839613
11	Thomas P, Battifora H, Manderino GL, Patrick J. A monoclonal antibody against neuron-specific enolase. Immunohistochemical comparison with a polyclonal antiserum. Am J Clin Pathol 1987; 88(2): 146–152 pmid: 3618548
12	Sapino A, Bussolati G. Is detection of endocrine cells in breast adenocarcinoma of diagnostic and clinical significance? Histopathology 2002; 40(3): 211–214 https://doi.org/10.1046/j.1365-2559.2002.01327.x pmid: 11895485
13	Maluf HM, Koerner FC. Carcinomas of the breast with endocrine differentiation: a review. Virchows Arch 1994; 425(5): 449–457 https://doi.org/10.1007/BF00197547 pmid: 7850068
14	Sanguinetti A, Santoprete S, Lucchini R, Triola R, Loreti F, Avenia N. A rare breast tumor: solid neuroendocrine carcinoma. Ann Ital Chir 2013; 84(1): 81–85 pmid: 22672972

Viewed

Full text

Abstract

Cited

Shared

Discussed